Search
Suzetrigine
go.drugbank.com/drugs/DB18927ApprovedInvestigational[A264953] On January 30, 2025, suzetrigine was approved by the FDA as a first-in-class non-opioid analgesic.[L52098]
Atibuclimab
go.drugbank.com/drugs/DB06546InvestigationalAtibuclimab (IC14) is a chimeric CD14 antibody investigated for the treatment of patients with severe sepsis.
Empagliflozin
go.drugbank.com/drugs/DB09038ApprovedInvestigationalThe development of C-glucoside phlorizin analogs remedied the issues observed in the previous generation, and led to the FDA approval of [canagliflozin] in 2013 and both [dapagliflozin] and empagliflozin
Anatibant
go.drugbank.com/drugs/DB05038ExperimentalAnatibant is a selective, very potent, small-molecule Bradykinin B2 receptor antagonist. It is developed for the for the treatment of traumatic brain injury (TBI).
Bicisate
go.drugbank.com/drugs/DB11164Approved[A32374] The complex of bicisate and technetium Tc99m as a kit was developed by Lantheus Medcl and FDA-approved on November 23, 1994.[L2029]
Cobalt
go.drugbank.com/drugs/DB14574ApprovedWithdrawnExcept for radioactive forms of cobalt and cobalamin, the FDA withdrew its approval for the use of drug products containing cobalt salts.[L43942]
Fremanezumab
go.drugbank.com/drugs/DB14041ApprovedInvestigational[L11749] It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018.
Agalsidase beta
go.drugbank.com/drugs/DB00103ApprovedInvestigational[A220343] Agalsidase beta was granted FDA approval on 24 April 2003.[L16383]
Lacosamide
go.drugbank.com/drugs/DB06218ApprovedInvestigational[A262681] Lacosamide was first approved by the European Commission in August 2008 and was later approved by the FDA in October 2008.
Products: Nra-lacosamideSparteine
go.drugbank.com/drugs/DB06727ApprovedWithdrawnSparteine is not currently FDA-approved for human use, and its salt, sparteine sulfate, is one of the products that have been withdrawn or removed from the market for reasons of safety or effectiveness